(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/203011 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/553* (2006.01)
C07D 498/04 (2006.01) *A61P 25/00* (2006.01)
C07D 498/10 (2006.01) *A61P 31/00* (2006.01)
A61P 17/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/025598

(22) International Filing Date:
02 April 2021 (02.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/004,404 02 April 2020 (02.04.2020) US

(71) Applicant: **RIGEL PHARMACEUTICALS, INC.** [US/US]; 1180 Veterans Boulevard, South San Francisco, California 94080 (US).

(72) Inventors: **DARWISH, Ihab**; c/o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San Francisco, California 94080 (US). **LUO, Zhushou**; c/o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San Francisco, California 94080 (US). **TAYLOR, Vanessa**; c/o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San Francisco, California 94080 (US).

(74) Agent: **LENTZ, Nelsen L.** et al.; c/o Eli Lilly And Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: RIP1K INHIBITORS

(57) Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

WO 2021/203011 A1